健择联合顺铂治疗晚期非小细胞肺癌的临床研究  

Combined gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer.

作　　者：王丽萍[1] 梅其达[1] 高国谦[1] 

机构地区：[1]郑州大学第一附属医院肿瘤科,450052

出　　处：《中华肿瘤杂志》2003年第6期590-591,共2页Chinese Journal of Oncology

摘　　要：目的　观察健择 (gemcitabine)联合顺铂治疗晚期非小细胞肺癌的疗效及毒性反应。方法　经病理细胞学证实的 46例晚期非小细胞肺癌患者采用健择 +顺铂方案 :健择 10 0 0mg/m2 ,第 1,8天 ;顺铂 80mg/m2 ,第 1天或分 3d应用 ,2 1d为 1个周期。结果　完全缓解 (CR) 1例 ,部分缓解 (PR) 2 0例 ,稳定 (SD) 19例 ,进展 (PD) 6例 ,总有效率 45.7%。初治 2 4例中 ,CR +PR 14例 ,有效率58.3 % ;复治 2 2例中 ,CR +PR 7例 ,有效率 3 1.8% ,两组差异有显著性 (P <0 .0 5)。毒副反应以白细胞及血小板下降为常见 ,但均可耐受。结论　健择联合顺铂对晚期非小细胞肺癌有较好疗效 。Objective To investigate the clinical efficacy and side effects of advanced non-small cell lung cancer(NSCLC) treated by combined gemcitabine and cisplati n. Methods Forty-six patients with locally advanced (Stage ⅢB) or metastatic (Stage Ⅳ) NSCLC were alloted to the study. The patients received gemcitabine 1 000 mg/m 2 on D 1,8, and cisplatin 80 mg on D 1～3 in the 21-day cycle. Results An object ive response was obtained in 46%(21/46) of patients (1 CR and 21 PR), whereas 19 p atients had stable disease and 6 patients showed progressive disease. The respon se rate was 58.3% in untreated patients and 31.8% was obtained in treated ones. Significant difference was observed betw een the two groups(P<0.05). The main toxicities were leukopenia and thrombocytopenia. Conclusion The combination of gemcitabine and cisplatin, being feasible and wel l-tolerated, should be taken as an energetic scheme in the treatment of advance d NSCLC.

关 键 词：健择 顺铂 治疗 晚期 非小细胞肺癌 临床研究 

分 类 号：R734.2[医药卫生—肿瘤]